1 The human P2Y 11 (hP2Y 11 ) receptor was stably expressed in two cell lines, 1321N1 human astrocytoma cells (1321N1-hP2Y 11 ) and Chinese hamster ovary cells (CHO-hP2Y 11 ), and its coupling to phospholipase C and adenylyl cyclase was assessed. 2 In 1321N1-hP2Y 11 cells, ATP promoted inositol phosphate (IP) accumulation with low mM potency (EC 50 =8.5+0.1 mM), whereas it was 15 fold less potent (130+10 mM) in evoking cyclic AMP production. 3 In CHO-hP2Y 11 cells, ATP promoted IP accumulation with slightly higher potency (EC 50 =3.6+1.3 mM) than in 1321N1-hP2Y 11 cells, but it was still 15 fold less potent in promoting cyclic AMP accumulation (EC 50 =62.4+15.6 mM) than for IP accumulation. Comparable dierences in potencies for promoting the two second messenger responses were observed with other adenosine nucleotide analogues. 4 In 1321N1-hP2Y 11 and CHO-hP2Y 11 cells, down regulation of PKC by chronic treatment with phorbol ester decreased ATP-promoted cyclic AMP accumulation by 60 ± 80% (P50.001) with no change in its potency. Likewise, chelation of intracellular Ca 2+ decreased ATP-promoted cyclic AMP accumulation by *45% in 1321N1-hP2Y 11 cells, whereas chelation had no eect on either the ecacy or potency of ATP in CHO-hP2Y 11 cells. 5 We conclude that coupling of hP2Y 11 receptors to adenylyl cyclase in these cell lines is much weaker than coupling to phospholipase C, and that activation of PKC and intracellular Ca 
Introduction
P2Y receptors are heptahelical, G protein-coupled receptors activated by extracellular nucleotides. These receptors are expressed in almost all cells and tissues, where they regulate a wide range of physiological processes. To date, ®ve subtypes of P2Y receptors have been cloned in humans (hP2Y 1, 2, 4, 6, 11 ) (North & Barnard, 1997; Harden, 1998; King et al., 1998) . The unambiguous association of a P2Y receptor subtype with a speci®c physiological eect has proven dicult to establish, in part due to the lack of subtype-selective agonists and antagonists. Thus, the pharmacological selectivities of these receptors have been de®ned by expressing individual subtypes of cloned P2Y receptors in null cell lines and determining the rank order of potencies of the natural agonists ATP, ADP, UTP and UDP, and with nucleotide analogues.
The hP2Y 1 receptor is highly selective for ADP and ATP and their 2-methylthio derivatives (Schachter et al., 1996; Leon et al., 1997; Palmer et al., 1998) . The triphosphatepreferring hP2Y 2 receptor is activated by both UTP and ATP with essentially equal potency, whilst ADP and UDP have little or no eect (Lustig et al., 1993; Nicholas et al., 1996) . UTP is a potent full agonist at the hP2Y 4 receptor, whereas ADP and UDP have little or no eect (Nguyen et al., 1995; Communi et al., 1996a; Nicholas et al., 1996) . Recently, we demonstrated that ATP is a competitive antagonist at the hP2Y 4 receptor, but is a potent full agonist at the rat P2Y 4 receptor (Kennedy et al., 2000) . The hP2Y 6 receptor is a pyrimidine-preferring receptor, with UDP more potent than UTP. ADP is a low potency agonist whereas ATP has no eect Communi et al., 1996b; Li et al., 1998) . Finally, the hP2Y 11 receptor is highly selective for ATP (Communi et al., 1997; .
All hP2Y receptor subtypes cloned to date are linked to activation of phospholipase C, generation of inositol phosphates (IPs), activation of protein kinase C (PKC) and release of intracellular Ca 2+ stores. In addition to coupling to phospholipase C, the hP2Y 11 receptor also couples to adenylyl cyclase, resulting in increased cyclic AMP synthesis (Communi et al., 1997; . ATP was reported to activate adenylyl cyclase with similar (Communi et al., 1997) or greater potency (Communi et al., 1999) compared to activation of phospholipase C. However, these second messenger assays were carried out in dierent cell lines expressing the hP2Y 11 receptor, i.e., 1321N1 human astrocytoma cells for IP accumulation and CHO-K1 cells for cyclic AMP accumulation. Given that agonist potencies are greatly in¯uenced by the level of receptor reserve (Kenakin, 1997; Palmer et al., 1998) , the eciency at which the hP2Y 11 receptor activates phospholipase C compared to adenylyl cyclase remains unestablished. Thus, the aim of this study was to determine the eciency with which the hP2Y 11 receptor couples to these two second messenger pathways in the same cell line and to determine the eects of intracellular Ca 2+ mobilization and phospholipase C activation on activation of adenylyl cyclase. A preliminary account of these results has been published (Kennedy et al., 1999) .
Methods
PCR amplification of the coding sequence of the hP2Y 11 receptor PCR primers complementary to the published sequence of the hP2Y 11 receptor (Communi et al., 1997) were used to amplify the coding sequence from 0.24 mg of human genomic DNA with Amplitaq DNA polymerase. The primers contained at their 5' ends either an EcoRI restriction site (5'-AGA-GAATTCCACCATGG ATCGAGGTGCCAAGTCCTGCC-CT-3'; upstream primer) or a XhoI restriction site (5'-GAGCTCGAGTCATTGGCTCAGCTCACGG-3'; downstream primer). In addition, the upstream primer also contained a consensus Kozak translation initiation consensus sequence (CACCATGG; Kozak, 1986) preceding the start ATG codon, all nine coding bases of exon 1 and the ®rst 18 bases of exon 2, whilst the downstream primer contained the ®nal 16 coding bases of exon 2 and the stop codon. The ampli®cation conditions were 948C for 3 min; 35 cycles of 948C for 30 s, 568C for 30 s, 728C for 70 s; and 7 min at 728C. The ampli®ed product was puri®ed, digested with EcoRI and XhoI, and ligated into the similarly digested retroviral expression vector, pLXSN. Individual clones encoding the receptor were sequenced using the Amplicycle Sequencing Kit, and the sequence obtained was identical to that reported by Communi et al. (1997) , except for the presence of a C in place of a T at position 240. This dierence was found in clones originating from separate ampli®cation reactions; however, it did not alter the protein sequence.
Expression of hP2Y 11 and hD1 receptors in 1321N1 and CHO-K1 cells Recombinant retroviral particles were produced by calcium phosphate-mediated transfection of PA317 packaging cells with the pLXSN vector (Miller & Rosman, 1989 ; GenBank accession no. M28248) containing hP2Y 11 cDNA (Comstock et al., 1997) . 1321N1 human astrocytoma cells and CHO-K1 cells were grown in monolayer culture at 378C in 5% CO 2 in high-glucose Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 5% fetal bovine serum (10% for CHO-K1 cells), 100 units ml 71 penicillin, 0.1 mg ml 71 streptomycin and 0.25 mg ml 71 amphotericin B. Cells were infected with retrovirus harbouring the hP2Y 11 coding sequence or with control retrovirus. CHO-K1 cells were pretreated with the glycosylation inhibitor tunicamycin (0.3 mg ml
71
) for 19 h prior to infection to inhibit the production of endogenous factors that suppress infection of hamster cells (Miller & Miller, 1992; ]. Following a 10 min incubation at 378C, the assay was terminated by aspirating the medium and adding 1 ml icecold trichloroactetic acid. [ 3 H]-cyclic AMP was isolated on Dowex and alumina columns as described previously (Harden et al., 1982) .
Statistics
Data in the text are expressed as the mean+s.d. for EC 50 values. Concentration-response curves were ®tted to the data by logistic (Hill equation), non-linear regression analysis (GraphPad Prism, San Diego, U.S.A.). Data were compared as appropriate by Student's paired t-test or by one-way analysis of variance and Tukey's comparison, with P50.05 considered to be statistically signi®cant.
Materials
AmpliTaq DNA polymerase and the Amplicycle Sequencing Kit were obtained from Perkin-Elmer (Norfolk, CT, U.S.A.). All tissue culture reagents and Hank's balanced salt solution were supplied by the Lineberger Comprehensive Cancer Center tissue culture facilities (University of North Carolina at Chapel Hill, NC, U.S.A.). ATP was purchased from Pharmacia (Piscataway, NJ, U.S.A.), ADP was from Roche Biochemicals (Indianapolis, IN, U.S.A.), 2MeSATP, 2MeSADP, ATPgS, ADPbS and forskolin were from RBI (Natick, MA, U.S.A.), PMA and BAPTA-AM were from Calbiochem (La Jolla, CA, U.S.A.) and PGE 1 , IBMX, and dopamine were from Sigma (St. Louis, MO, U.S.A.). Stock solutions of ADP and 2MeSADP (10 mM) were incubated with 50 U ml 71 hexokinase (Roche Biochemicals, Indianapolis, IN, U.S.A.) in DMEM high glucose medium for 2 h before use to eliminate triphosphate contamination. In addition, assay solutions contained 5 U hexokinase ml
71
. Similarly, stock solutions (10 mM in DMEM high glucose) of the nucleotidase-resistant nucleotide analogues, ATPgS and ADPbS, were treated with 3 U ml 71 apyrase (Sigma-Aldrich, St. Louis, MO, U.S.A.) for 30 min before use.
Results

Properties of the hP2Y 11 receptor expressed in 1321N1 cells
1321N1 cells infected with viruses produced from pLXSN vector alone showed no responses to ATP (data not shown). ATP increased IP accumulation in a concentration-dependent manner (EC 50 =8.5+0.1 mM) in 1321N1 cells expressing the hP2Y 11 receptor (Figure 1 ). At higher concentrations, ADP also promoted IP accumulation, but only to levels *35% of those achieved with maximal concentrations of ATP (basal subtracted). ATP also promoted cyclic AMP accumulation, with an EC 50 of 130+10 mM (Figure 1 ). Thus, in 1321N1-hP2Y 11 cells, ATP promotes IP accumulation with 15 fold greater potency than it promotes cyclic AMP accumulation. In contrast to its ability to promote IP accumulation, ADP did not increase cyclic AMP levels in these cells. Concentrationresponse curves for ATP-promoted cyclic AMP accumulation (Figures 1 ± 4) were steep. The reason(s) for this deviation from law of mass interaction at a single site has not been pursued.
Effects of ATP in CHO-K1 cells expressing the hP2Y 11 receptor
To ensure that cell-speci®c dierences do not account for the dierential sensitivity of ATP in promoting the two second messenger responses, we also expressed the hP2Y 11 receptor in CHO-K1 cells. CHO-K1 cells express a P2Y 2 receptor that responds to ATP (Iredale & Hill, 1993) , but expression of the hP2Y 11 receptor in these cells gave rise to ATP-promoted increases in IP accumulation 20 fold higher than those in vector-infected cells (Figure 2A ). This allowed us to address the issue of dierential coupling of the hP2Y 11 receptor in an additional cell line.
In CHO-hP2Y 11 cells, ATP increased IP accumulation in a concentration-dependent manner and with a potency slightly greater than in 1321N1-hP2Y 11 cells (EC 50 =3.6+1.3 mM) ( Figure 2B ; Table 1 ). ATP also evoked cyclic AMP synthesis with a potency greater than in 1321N1 cells (EC 50 = 62+16 mM), but still 15 fold less than the EC 50 for inositol lipid hydrolysis. Thus, similar dierences in coupling of the hP2Y 11 receptor to adenylyl cyclase and phospholipase C were observed in two cell lines, strongly suggesting that these dierences are an inherent property of the receptor. ADP promoted inositol lipid hydrolysis (EC 50 =50.1+20.6 mM) to (1) Differential coupling of the human P2Y 11 receptor A.-D. Qi et allevels *50% of that of the maximal levels promoted by ATP ( Figure 2B ). In contrast to 1321N1-hP2Y 11 cells, ADP increased cyclic AMP levels in CHO-hP2Y 11 cells, although the concentration-response curve did not reach a clear maximum.
Coupling efficiency of the hP2Y 11 receptor activated with other adenine nucleotides To determine whether other hP2Y 11 agonists also exhibited dierences in potency for promotion of IP and cyclic AMP accumulation, concentration-response curves of several adenine nucleotide analogues, including ATPgS, ADPbS, 2MeSATP, and 2MeSADP, were generated. All of these nucleotide analogues were considerably more potent (7 ± 20 fold) for promotion of IP accumulation than cyclic AMP accumulation (Table 1 ). The rank order of potency of these agonists for stimulation of IP accumulation (ATPgS42MeSATP4ATP*ADPbS42MeSADP4ADP) is similar to that previously reported for the hP2Y 11 receptor (ATPgS4ATP4ADPbS42MeSATP; Communi et al., 1999) with the exception of 2MeSATP, which had a higher potency relative to the other agonists in the present experiments.
Effects of phosphodiesterase inhibitors on hP2Y 11 receptor signalling
These data dier from those reported by Communi et al. (1997; , in which ATP was either equipotent or even more potent for stimulating cyclic AMP accumulation compared with IP production. One possible explanation of this discrepancy is that in the present study IBMX was used to inhibit cyclic AMP breakdown by phosphodiesterase, but rolipram was employed by Communi et al. (1997) . To test the possibility that IBMX, an antagonist at adenosine receptors (Bruns et al., 1986; Ukena et al., 1986; Con & Spealman, 1989) , also acts as an antagonist at the hP2Y 11 receptor, we included 200 mM IBMX in the incubation medium during IP assays. However, its inclusion had no eect on the ability of ATP to evoke IP synthesis (data not shown), indicating that IBMX is not an antagonist at the hP2Y 11 receptor and its use does not underlie the discrepancy between the present study and those of Communi et al. (1997; .
Influence of PKC activation and intracellular Ca 2+ mobilization on cyclic AMP accumulation in 1321N1-hP2Y 11 and CHO-hP2Y 11 cells
Because the hP2Y 11 receptor couples more eciently to phospholipase C than to adenylyl cyclase, inositol lipid hydrolysis is near maximal at concentrations of ATP that only minimally increase cyclic AMP accumulation. Thus, the downstream signalling eects of ATP-promoted inositol lipid hydrolysis (i.e., intracellular Ca 2+ mobilization and PKC activation) potentially in¯uence cyclic AMP accumulation. Therefore, we investigated the eects of both intracellular Ca 2+ mobilization and PKC activation on the capacity of ATP to promote cyclic AMP accumulation in both 1321N1-hP2Y 11 and CHO-hP2Y 11 cells. Cells were treated with BAPTA-AM (50 mM) for 10 min to chelate intracellular Ca 2+ , with the phorbol ester PMA (1 mM) for 20 h to down regulate PKC, or with both agents, and cyclic AMP accumulation was measured following challenge of the cells with 300 mM ATP. In 1321N1-hP2Y 11 cells, intracellular Ca 2+ chelation decreased ATP-promoted cyclic AMP accumulation by 41+5% (P50.01), whereas downregulation of PKC resulted in a 57+1% decrease (P50.001; Figure 3A) . Combination of both treatments caused a slight but signi®cant further decrease in cyclic AMP accumulation (66+2%, P50.01) compared to PMA treatment alone. In contrast, intracellular Ca 2+ chelation had no eect on ATPpromoted cyclic AMP accumulation in CHO-hP2Y 11 cells, whereas downregulation of PKC resulted in a 58+4% decrease (P50.01) in ATP-promoted cyclic AMP accumulation ( Figure 4A ). The eect of both treatments was not signi®cantly dierent from PMA treatment alone.
To determine whether coupling of the hP2Y 11 receptor to inositol lipid hydrolysis is responsible for the potentiation of cyclic AMP accumulation in these cells, we measured the eects of intracellular Ca 2+ chelation or down regulation of PKC on other Gs-coupled receptors. Thus, we generated 1321N1 cells stably expressing the human D1 dopamine receptor, which couples exclusively to Gs/adenylyl cyclase, and determined the eects of intracellular Ca 2+ chelation and down regulation of PKC on dopamine-promoted increases in cyclic AMP accumulation. In contrast to ATP-promoted Figure 3B ). In CHO-K1 cells, an endogenously expressed Gs-coupled prostaglandin receptor was utilized to test the eects of intracellular Ca 2+ chelation and down regulation of PKC on cyclic AMP accumulation. PGE 2 -promoted cyclic AMP accumulation also was not aected in PMA/BAPTA-AMtreated cells ( Figure 4A ). These data indicate the potentiation of ATP-promoted cyclic AMP accumulation is due to the coupling of the hP2Y 11 receptor to inositol lipid hydrolysis.
To characterize further the in¯uence of PKC and intracellular [Ca 2+ ] on ATP-promoted cyclic AMP accumulation, we compared the concentration-response curves of ATP in vehicle versus PMA-and BAPTA-AM-treated 1321N1-hP2Y 11 and CHO-hP2Y 11 cells. In 1321N1-hP2Y 11 cells, the response to 1 mM ATP was decreased by nearly 80% in PMA/BAPTA-AM-treated cells, but the concentration-response curve of treated cells did not reach a maximum and an EC 50 could not be calculated ( Figure 3C ). In CHOhP2Y 11 cells, the maximal response to ATP was decreased by *60% in PMA-treated cells, whereas the EC 50 values were not signi®cantly dierent from one another ( Figure 4B ).
We also investigated the eect of short term activation of PKC on cyclic AMP accumulation in both cell lines. Consistent with the eect of PKC downregulation, which decreased cyclic AMP accumulation, activation of PKC by short-term addition of PMA (1 mM, 10 min) signi®cantly potentiated ATP-, PGE 1 -, and forskolin-promoted increases in cyclic AMP accumulation in CHO-hP2Y 11 cells ( Figure  5A ). To verify that receptor-stimulated intracellular Ca 2+ mobilization and PKC activation could increase adenylyl cyclase activity, cyclic AMP accumulation was measured in 1321N1-hD1 cells treated with dopamine alone or with carbachol, which activates an endogenous M3 muscarinic receptor coupled to Gq/phospholipase C ( Figure 5B ). M3 receptor activation alone had no aect on cyclic AMP levels, whereas M3 receptor activation increased dopamine-stimulated cyclic AMP accumulation by nearly 2 fold (P50.001), consistent with the potentiating eects of PKC activation and intracellular Ca 2+ mobilization on adenylyl cyclase activity.
Discussion
We show here that the hP2Y 11 receptor, when exogenously expressed in either 1321N1 or CHO-K1 cells, couples to both phospholipase C and adenylyl cyclase with marked dierences in eciency. That is, ATP promotes IP accumulation in both cell lines with 15 fold greater potency than it promotes cyclic AMP accumulation. In addition, other adenine nucleotides promoted both second messenger responses in CHO-hP2Y 11 cells with similar dierences (7 ± 20 fold) in potency. The marked dierences in EC 50 values for agonistpromoted IP and cyclic AMP accumulation of the hP2Y 11 receptor contrasts with another dual-coupled P2Y receptor, an avian p2y receptor that simultaneously activates phospholipase C and inhibits adenylyl cyclase (Boyer et al., 1997; . This avian p2y receptor couples with similar eciency to both inhibition of adenylyl cyclase and activation of phospholipase C.
The data reported here are dierent from those of Communi and colleagues, who have reported that ATP has either similar (Communi et al., 1997) or even greater (Communi et al., 1999) potency at the hP2Y 11 receptor for promotion of cyclic AMP accumulation relative to inositol lipid hydrolysis. However, in those studies IP accumulation was measured in transfected 1321N1 cells, whereas cyclic AMP accumulation was measured in transfected CHO-K1 cells. It was reported in Communi et al. (1999) that when both IP and cyclic AMP accumulation were measured in the same transfected 1321N1 cell line, ATP promoted cyclic AMP accumulation with much lower potency than it promoted inositol phosphate accumulation. Thus, the dierences in potencies for promoting the two second messenger pathways in the same cell line reported in Communi et al. (1999) are similar to the data presented here, although no data were shown and this observation was not investigated further. Moreover, the authors reported that CHO-K1 cells transfected with the hP2Y 11 receptor did not show signi®cant enhancement of ATP-promoted IP accumulation over the response observed in untransfected cells, making them unsuitable to characterize the coupling to inositol lipid hydrolysis in this cell line. Thus, no direct comparison of EC 50 values for agonist-promoted second messenger responses could be made. The lack of a signi®cant response in transfected CHO-K1 cells contrasts with the data reported here, in which ATP application to CHO-K1 cells expressing the hP2Y 11 receptor raised IP levels to 20 fold higher than those in vector-infected cells. The reasons for these dierences are not clear, but may be due to the dierent expression systems or dierences in the parental cell lines used.
The EC 50 of ATP for promoting IP accumulation in 1321N1-hP2Y 11 cells in this study was 4 ± 8 fold greater compared to previous studies (Communi et al., 1997; . Similarly, ADP was inactive in the earlier studies, but increased IP levels here. This suggests greater receptor reserve of the hP2Y 11 receptor or an increase in its coupling to G q/11 in the population of cells we used. ADP had no eect on cyclic AMP levels in 1321N1-hP2Y 11 cells, but this was probably due to the much lower coupling eciency of the hP2Y 11 receptor to adenylyl cyclase in these cells and the lower potency and ecacy of ADP compared with ATP. Likewise, the ability of ADP to promote cyclic AMP accumulation in CHO-K1 cells infected with hP2Y 11 receptor, together with the greater potency of ATP for promotion of inositol lipid hydrolysis in CHO-hP2Y 11 versus 1321N1-hP2Y 11 cells, is consistent with a higher level of expression of the hP2Y 11 receptor in CHO-K1 cells than in 1321N1 cells. Higher levels of expression of the hP2Y 11 receptor in CHO-K1 cells than in 1321N1 cells may explain the greater potency of ATP for promotion of cyclic AMP accumulation than for IP accumulation reported in earlier studies (Communi et al., 1999) . The in¯uence of receptor density on coupling eciency of the hP2Y 11 receptor is unknown, but possibly could be addressed with an inducible expression system.
It is possible that the activity of ADP in our experiments was due to either contamination of ADP stocks with ATP or that ADP was enzymatically converted to ATP by ectonucleoside diphosphokinase activity from UTP or CTP released by the cells into the medium. However, we believe this possibility to be unlikely, since ADP stocks were treated with hexokinase and hexokinase also was included in the assay medium. We have shown previously that these precautions are sucient to eliminate ATP contamination in ADP stocks and to prevent bioconversion in the assay medium . Furthermore, we have shown recently that ADP is a partial agonist for promoting Ca 2+ mobilization in 1321N1-hP2Y 11 cells under conditions that minimize nucleotide metabolism and bioconversion (Qi et al., manuscript in preparation). Thus, ADP appears to be a partial agonist at the hP2Y 11 receptor.
We also show here that concomitant stimulation of inositol lipid hydrolysis, which increases intracellular Ca 2+ mobilization and activates PKC, markedly potentiates the maximal levels of cyclic AMP accumulation without changing agonist potency. In 1321N1-hP2Y 11 cells, both chelation of intracellular Ca 2+ and downregulation of PKC markedly inhibit ATP-promoted adenylyl cyclase activity, whereas in CHOhP2Y 11 cells, ATP-promoted adenylyl cyclase activity is refractory to [Ca 2+ ] but is decreased when PKC is downregulated. This eect is speci®c to the hP2Y 11 receptor; cyclic AMP accumulation promoted by Gs-coupled receptors that do not stimulate inositol lipid hydrolysis, such as hD1 dopamine or PGE 2 receptors, is not aected by BAPTA-AM or chronic PMA treatment. In addition, cyclic AMP accumulation promoted by these Gs-coupled receptors was potentiated following acute treatment of cells with PMA or following co-activation of an endogenous Gq-coupled muscarinic receptor. The most parsimonius explanation of these results is that receptor-promoted increases in intracellular Ca 2+ mobilization and/or PKC activation potentiates adenylyl cyclase activity in 1321N1 and CHO-K1 cells. Several studies have documented cross-talk between Gsand Gq-coupled receptors (Ho et al., 1988; Donaldson et al., 1988; Alexander et al., 1992; Klinger et al., 1998) . However, these studies focused on the consequences of activation of two distinct G protein-coupled receptors, one coupled solely to phospholipase C and the other coupled solely to activation of adenylyl cyclase. In contrast, with the hP2Y 11 receptor cross-talk between signalling pathways occurs following activation of a single receptor.
The dierences in sensitivity to PKC down-regulation or Ca 2+ chelation in 1321N1 and CHO-K1 cells are likely due to the dierent isoforms of adenylyl cyclase expressed in these cells. For example, adenylyl cyclase types II, III, V, or VII are stimulated by PKC, whereas types I, III and VIII are stimulated by Ca 2+ (Tang & Hurley, 1998; Cooper et al., 1995) Thus, the type(s) of adenylyl cyclase expressed in a cell line or tissue can have marked in¯uence on the maximal levels of hP2Y 11 -promoted cyclic AMP accumulation. A recent study in HL-60 cells (Suh et al., 2000) , which endogenously express the P2Y 11 receptor, showed that acute treatment with PMA potentiated dATP-, forskolin-and cholera toxin-mediated increases in cyclic AMP accumulation, suggesting that these cells express an isoform of adenylyl cyclase that is potentiated by PKC. Thus, potentiation of adenylyl cyclase in HL-60 cells by PKC is consistent with our data in both CHO-K1 and 1321N1 cells.
There are relatively few examples of receptors that couple to the activation of both phospholipase C and adenylyl cyclase. These include receptors for the pituitary adenylyl cyclase-activating polypeptide (PACAP; Spengler et al., 1993; Pisegna & Wank, 1996) , luteinizing hormone (LH; Gudermann et al., 1992) , calcitonin (CT; Houssami et al., 1994) , thyrotropin (TSH; Van Sande et al., 1990) , parathyroid hormone (PTH; Abou-Samra et al., 1992) and three tachykinins (substance P, substance K, and neuromedin K; Nakajima et al., 1992) . Interestingly, all of these receptors are class 1b receptors, which recognize peptide hormones as their cognate ligands (Bockaert & Pin, 1999) . Although the hP2Y 11 receptor is activated by small nucleotides, sequence analysis indicates that P2Y receptors are more closely related to peptide receptors than they are to receptors for small molecules such as biogenic amines and adenosine (Lustig et al., 1993) . Thus, dual coupling to phospholipase C and adenylyl cyclase may be con®ned to a small subset of class 1b receptors.
These dual-coupled receptors also show dierent eciencies in their coupling to cyclic AMP and IP accumulation. In contrast to the P2Y 11 receptor, the PACAP, LH, CT, and TSH receptors couple more eciently (6 ± 40 fold) to cyclic AMP accumulation than to inositol lipid hydrolysis (Spengler et al., 1993; Pisegna & Wank, 1996; Gudermann et al., 1992; Oermans et al., 1996) . However, the tachykinin receptors showed similar coupling eciencies as the hP2Y 11 receptor, in which stimulation of inositol lipid hydrolysis occurred at agonist concentrations 10 fold lower than for stimulation of cyclic AMP accumulation (Nakajima et al., 1992) . To date, no studies have shown whether these dierences have any functional relevance for the physiological activities of the receptors.
In conclusion, the hP2Y 11 receptor is coupled to both phospholipase C and adenylyl cyclase, but is more eciently coupled to phospholipase C. In addition, the capacity of ATP to promote cyclic AMP accumulation in 1321N1-hP2Y 11 and CHO-hP2Y 11 cells is markedly potentiated by mobilization of intracellular Ca 2+ and/or activation of PKC as a consequence of coupling to Gq/phospholipase C.
